I recieved a press release from ProBioGen Ag, Berlin, Germany this morning touting its new Glyco-Engineering technology, GlymaxX, for creating afucosylated antibodies with increased potency. GlymaxX will enhance ADCC effector function and therefore increase cell-killing capability of therapeutic antibodies.
GlymaxX employs a heterologous enzyme that interrupts the fucose biosynthesis pathway (Glycobiology, 2010 Dec; 20(12):1607-18). Uniquely, GlymaxX can be applied to already existing antibody producing cell lines without altering their productivity. The GlymaxX technology has been confirmed in feasibility studies with several major European pharmaceutical companies. The technology is available under license.
See here for more detailed information on the technology.
Posted by Bruce Lehr November 11th 2010.